FDA Safety Update · November 9, 2026
New GLP-1 warnings about a rare eye condition.
The FDA is requiring warning-label changes for GLP-1 receptor agonist medicines, including Ozempic, Wegovy, Mounjaro and Zepbound, about a potential increased risk of non-arteritic anterior ischemic optic neuropathy (NAION). This rare eye condition involves reduced blood flow to the optic nerve and can cause sudden, painless vision loss in one eye, including permanent vision loss.
The FDA advises people with sudden vision loss, blurred or missing areas of vision, or other new visual disturbances to contact a healthcare professional right away. People who develop NAION should discuss with their healthcare professional whether to continue or stop their GLP-1 medicine; this is not a blanket recommendation for everyone to stop treatment.
Read moreShow less
This is a regulatory safety update, not a new individual trial. In its analysis of 126 randomized controlled trials, the FDA reported 6.4 probable NAION cases per 100,000 person-years among GLP-1 users, compared with 3.8 among people receiving placebo or a non-GLP-1 glucose-lowering medicine. These rates describe cases over accumulated follow-up time, not a percentage of everyone taking the medicines. Events were rare, and risk factors overlap with conditions common in people using GLP-1 medicines. The evidence does not establish a definitive cause-and-effect relationship.
This summary is for general education. It does not provide medical advice, diagnose conditions, recommend treatment, or endorse a medication, provider, product, or service.

